IQVIA HOLDINGS INC. reported second-quarter 2026 results with revenue up 8.7% year over year to $4.37B while diluted EPS was $1.53 and net income was $258M, compared with $4.02B, $1.54 and $266M in the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$4.37B$4.02B8.7% | Net income²$258M$266M(3%) | Diluted EPS³$1.53$1.54(0.6%) |
¹ Reported as “Revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share attributable to common stockholders”.
Business Highlights
- Consolidated revenues grew 8.7% in the quarter and 8.6% year-to-date, driven by an 8.6% increase in Commercial and 8.8% growth in R&D in the quarter.
- The company reorganized into two reporting segments—Commercial Solutions and R&D Solutions—effective Jan. 1, 2026 to better align operations.
- Growth momentum was supported by patient solutions, commercial engagement services, clinical services and higher lab testing volumes.
- Restructuring actions are underway to streamline global operations, reduce overcapacity and realign resources through 2027.
- R&D contracted backlog modestly increased to $34.2B, with about $9.2B expected to convert to revenue in the next 12 months.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.